Specifically, for the ICI-treated patients of the MSK dataset, ROS1 mutation was detected in 20.0% of melanoma patients, and the high mutation frequency was also confirmed within different subtypes of melanoma, including cutaneous melanoma, head and neck mucosal melanoma, and melanoma of unknown primary (Figure 1C). Here, ROS1 is linked to cutaneous melanoma.